Bemarituzumab (FUT8-KO)
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa[1].
Product Specifications
UNSPSC
12352203
Target
FGFR; Interleukin Related
Type
Reference compound
Related Pathways
Immunology/Inflammation; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bemarituzumab-fut8-ko.html
Purity
99.74
Smiles
[Bemarituzumab(FUT8-KO)]
Molecular Weight
(143.86 kDa)
References & Citations
[1]Xiang H, et al., Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021 Jan-Dec;13 (1) :1981202.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
K6881004 1.0 µg DNA
Myo5a sgRNA CRISPR Lentivector (Rat) (Target 3)
Sign In for Pricing
View Details 
E38MA4209 100 µL
Recombinant CaMK2 alpha/beta/delta/gamma Rabbit mAb
Sign In for Pricing
View Details FAB8166I 0.1 mL
Rat Monoclonal Semaphorin 4A Antibody (757129) [Janelia Fluor 549]
Sign In for Pricing
View Details 